An Incidental Chronic Total Occlusion With Mild Symptoms: Medical Therapy First or CTO-PCI?
The occlusion is real and his symptoms are real, but his mild symptom burden, preserved EF, and reduced kidney function all point toward asking how far medical therapy can go before reaching for the procedure.
A.B., a 63-year-old man, has run the same hardware store on the same corner for over twenty years, and he measures his health mostly by whether he can still carry a box of tile up from the basement stock room without stopping. Three weeks ago he was admitted with an NSTEMI, found to have a significant proximal LAD lesion that was stented without complication. The angiogram done at that time also showed a chronic total occlusion of his right coronary artery — old, well-collateralized, not the culprit for his acute event, and previously unknown to him or his primary care physician.
He has recovered well from the stent and is back on his feet, but he's noticed a tightness in his chest climbing the stairs to his store's second-floor storage — mild, reproducible, resolving with rest, present a few times a week rather than daily. His ejection fraction is preserved at 58%, and aside from the CAD itself his main other finding is chronic kidney disease, stage 3a, picked up incidentally on the labs drawn during his admission. That detail matters more than it might otherwise: CTO-PCI cases run longer and typically require more contrast than a straightforward single-vessel intervention, and his kidneys are already operating with less reserve than they were five years ago. The question his cardiology team is weighing isn't whether the RCA occlusion is real — it plainly is — but whether opening it is actually the right next step for a man whose symptoms are mild, whose EF is normal, and whose kidneys would have to absorb the cost of finding out.
In the cath lab conference, three weeks out
He's symptomatic, the occlusion is real and well-visualized, and CTO-PCI success rates at experienced centers are high enough now that I don't think we should default to calling this a medical-therapy-only case just because his EF is preserved. Opening the RCA is likely to meaningfully improve his stair-climbing symptoms in a way that further anti-anginal titration may not.
If his symptoms were resolving on his current regimen, or if he had no symptoms at all, I wouldn't be proposing this — an incidentally found CTO in an asymptomatic patient with preserved EF is not, on its own, a revascularization indication. The case here rests on real, reproducible symptoms that haven't been given a fair trial of escalated medical therapy yet.
That's exactly my concern — we haven't actually tried escalating his medical therapy yet. He's on a modest beta-blocker dose and nothing else anti-anginal. ISCHEMIA and the trials before it were fairly consistent that in stable disease with preserved EF, revascularization doesn't reduce death or MI compared to optimal medical therapy, even though it can help symptoms faster. I'll grant the caveat up front — ISCHEMIA enrolled stable patients and excluded recent acute coronary syndromes, so at three weeks out he sits just outside the enrolled population, and his culprit vessel is already treated. Given that his kidney function is already reduced, I'd want to see what titrating his beta-blocker and adding a second anti-anginal agent does before accepting the contrast load and procedural risk of a CTO attempt.
I take the point that CTO-PCI can relieve symptoms faster than medical titration — but 'faster' isn't the same as 'necessary' for a man whose symptoms are mild and occur a few times a week, not daily and not at rest. I'd rather spend a few weeks finding out whether medical therapy gets him there before exposing his kidneys to a procedure that may not end up changing anything he actually experiences.
There's a real middle path here that doesn't require picking a winner today. His metoprolol is at a starting dose, not a ceiling dose — there's room to titrate before we've genuinely tested medical therapy. I'd double it to 50 mg now and again to 100 mg at two weeks if his heart rate and blood pressure allow, rather than jumping four-fold in one step. Adding amlodipine gives us a second anti-anginal mechanism without any contrast or procedural exposure at all. If his symptoms are still limiting him after that trial, the CTO conversation is stronger and better-informed than it is today, and his eGFR gets time to demonstrate whether 48 is stable or still trending.
Agreed: metoprolol doubled to 50 mg now and to 100 mg at two weeks if tolerated, amlodipine added, and a follow-up visit set for six weeks to reassess his stair-climbing symptoms specifically.
Not agreed on what happens if that trial doesn't fully resolve his symptoms:
The CTO stays medically managed indefinitely, reassessed only if his clinical picture changes.
CTO-PCI moves forward, with his renal function rechecked immediately beforehand to confirm 48 has held rather than declined further.
Either way, his eGFR will be rechecked at the six-week visit.